FDA’s Final Risk-Benefit Guidance Excludes 510(k)s, Adds De Novo Petitions
This article was originally published in The Gray Sheet
Device center reviewers will begin applying the guidance to incoming PMA and de novo submissions and to submissions already under review with decisions beginning on May 1.
You may also be interested in...
In an Aug. 24 guidance, US FDA says it's swayed by what it and patients believe are the magnitude and duration of benefits of a device or diagnostic, versus how troublesome any adverse events might be, and patient tolerance for them. The document describes factors the agency relies on when making risk-benefit decisions about PMA submissions and de novo classifications. Further, the agency expects sponsors and staff to recalculate the benefits and risks at every step along the device development process – and beyond.
The public-private Medical Device Innovation Consortium issued a report outlining strategies for incorporating patient preference data into device applications.
Device center officials cite a host of formal and informal actions available under existing legislative authority to ensure that development and review of companion diagnostics do not hinder the ability of FDA-designated breakthrough drugs from coming to market.